OncoMatch/Clinical Trials/NCT06840704
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Is NCT06840704 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for non small cell lung cancer.
This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: thoracic radiotherapy
Lab requirements
Blood counts
anc ≥ 1.5 × 10^9/l; plt ≥ 80 × 10^9/l; hb ≥ 90 g/l
Kidney function
bun and cr ≤ 1.5 × uln, with creatinine clearance ≥ 50 ml/min (calculated using the cockcroft-gault formula)
Liver function
tbil ≤ 1.5 × uln; alt and ast ≤ 2 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06840704 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior thoracic radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify